CPAP治疗对心血管疾病合并OSA患者肾功能的影响
本研究为SAVE试验子研究,纳入200例中重度OSA合并心血管疾病患者,比较CPAP联合常规治疗与单纯常规治疗对肾功能的影响。中位随访4.4年,两组eGFR变化及尿白蛋白肌酐比、严重肾脏不良事件均无差异,CPAP依从性不影响结果。
要点
- CPAP治疗未显著改善心血管疾病合并OSA患者的eGFR下降趋势
- 两组尿白蛋白肌酐比及严重肾脏不良事件发生率无差异
- CPAP依从性水平未影响肾脏结局
核心结论
- 对心血管疾病合并OSA患者,CPAP治疗不改变肾功能或肾脏不良事件的发生。
研究设计与样本
- 国际SAVE试验子研究,2717例中重度OSA合并冠心病或脑血管病患者随机分组,本子研究比较CPAP组(n=102)与常规治疗组(n=98)。
主要发现
- 200例子研究参与者(平均年龄64岁,4%氧减指数中位数20次/h,基线平均eGFR 82 ml/min/1.73 m2)中,CPAP组eGFR年变化中位数-1.64(-3.45至-0.740)ml/min/1.73 m2/yr,常规治疗组-2.30(-4.53至-0.71)ml/min/1.73 m2/yr,P=0.21。
- 中位随访4.4年,研究结束时尿白蛋白肌酐比及试验期间严重肾脏或泌尿不良事件发生率组间无差异。
- CPAP依从性水平未影响上述发现。
临床怎么用
- 不应以改善肾功能为目的对心血管疾病合并OSA患者常规处方CPAP。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Obstructive sleep apnea (OSA) is associated with impaired renal function, but uncertainty exists over whether OSA treatment can influence renal outcomes. OBJECTIVES: To determine the effects of continuous positive airway pressure (CPAP) on renal function in subjects with coexisting OSA and cardiovascular disease. METHODS: This was a substudy of the international SAVE (Sleep Apnea Cardiovascular Endpoints) trial, in which 2,717 patients with moderate to severe OSA and established coronary or cerebrovascular disease were randomized to receive either CPAP plus usual care or usual care alone. Renal function and adverse renal events were compared between the CPAP (n = 102) and usual care (n = 98) groups. Glomerular filtration rate was estimated at randomization and at the end of follow-up, and the urinary albumin-to-creatinine ratio was measured at study exit. MEASUREMENTS AND MAIN RESULTS: In 200 substudy participants (mean age, 64 yr; median, 4% oxygen desaturation index; 20 events/h; mean estimated glomerular filtration rate at baseline, 82 ml/min/1.73 m2), the median (interquartile range) changes in estimated glomerular filtration rate (ml/min/1.73 m2/yr) were -1.64 (-3.45 to -0.740) in the CPAP group and -2.30 (-4.53 to -0.71) in the usual care group (P = 0.21) after a median of 4.4 years. There were no between-group differences in end-of-study urinary albumin-to-creatinine ratio or in the occurrence of serious renal or urinary adverse events during the trial. The level of CPAP adherence did not influence the findings. CONCLUSIONS: CPAP treatment of OSA in patients with cardiovascular disease does not alter renal function or the occurrence of renal adverse events. Clinical trial registered with www.clinicaltrials.gov (NCT00738179).
引用
- Loffler KA, Heeley E, Freed R, et al. Effect of Obstructive Sleep Apnea Treatment on Renal Function in Patients with Cardiovascular Disease. Am J Respir Crit Care Med. 2017. PMID: 28743190. doi:10.1164/rccm.201703-0603OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。